BioMark Diagnostics at the equities.com Small-Cap Stars Conference at the NASDAQ MarketSite

BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences

October 4, 2026

BioMark Diagnostics Inc. announces its upcoming participation in two premier Canadian life sciences events: MSACL 2026 and BIOHorizon 2026 . The company will present advances in its metabolomics-based liquid biopsy

BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy

August 25, 2026

BioMark Diagnostics reports five peer-reviewed publications in nine months validating its metabolomics liquid biopsy for early NSCLC detection. New studies show high accuracy (up to 96.9% ROC-AUC), compact AI/ML panels,

BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day

July 31, 2026

BioMark Diagnostics endorses the 2026 World Lung Cancer Day global call for equitable access to early screening. The company advances its metabolomics-based liquid biopsy platform, validated in Quebec and the

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

June 23, 2026

BioMark Diagnostics receives formal patent allowances from CIPO (Canada) and the EPO (Europe) for its early-stage lung cancer blood test. The metabolomics platform and algorithm are validated across more than

BioMark™ Diagnostics

BioMark Diagnostics at the equities.com Small-Cap Stars Conference at the NASDAQ MarketSite

Contact BioMark Diagnostics

Canadian Stock Exchange

OTC Markets

Frankfurt Stock Exchange

Share This Post

Related News

BioMark Announces Participation in upcoming MSACL 2026 and BIOHorizon 2026 Life Sciences Conferences

BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy

BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day

BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test

Sign up for the latest BioMark news

Company

Our Sciences

Investors

Policies & Notices